Rosiglitazone Treatment Reduces Diabetic Neuropathy in Streptozotocin-Treated DBA/2J Mice
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Diabetic neuropathy (DN) is a common complication of diabetes. Currently, there is no drug treatment to prevent or slow the development of DN. Rosiglitazone (Rosi) is a potent insulin sensitizer and may also slow the development of DN by a mechanism independent of its effect on hyperglycemia. A two by two design was used to test the effect of Rosi treatment on the development of DN. Streptozotocin-induced diabetic DBA/2J mice were treated with Rosi. DN and oxidative stress were quantified, and gene expression was profiled using the Affymetrix Mouse Genome 430 2.0 microarray platform. An informatics approach identified key regulatory elements activated by Rosi. Diabetic DBA/2J mice developed severe hyperglycemia, DN, and elevated oxidative stress. Rosi treatment did not affect hyperglycemia but did reduce oxidative stress and prevented the development of thermal hypoalgesia. Two novel transcription factor binding modules were identified that may control genes correlated to changes in DN after Rosi treatment: SP1F_ZBPF and EGRF_EGRF. These targets may be useful in designing drugs with the same efficacy as Rosi in treating DN but with fewer undesirable effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Cited by
New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain
Feldman, E. L., Nave, K.-A., Jensen, T. S., & Bennett, D. L. H. (2017) · Neuron · doi:10.1016/j.neuron.2017.02.005 · Cited by 915
Self-citationDiabetic neuropathy: cellular mechanisms as therapeutic targets
Vincent, A. M., Callaghan, B. C., Smith, A. L., & Feldman, E. L. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.137 · Cited by 566
Self-citationMechanisms of disease: The oxidative stress theory of diabetic neuropathy
Figueroa-Romero, C., Sadidi, M., & Feldman, E. L. (2008) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-008-9104-2 · Cited by 284
Self-citationDyslipidemia-Induced Neuropathy in Mice
Vincent, A. M., Hayes, J. M., McLean, L. L., Vivekanandan-Giri, A., Pennathur, S., & Feldman, E. L. (2009) · Diabetes · doi:10.2337/db09-0047 · Cited by 264
Self-citationInflammation as a Therapeutic Target for Diabetic Neuropathies
Pop-Busui, R., Ang, L., Holmes, C., Gallagher, K., & Feldman, E. L. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0727-5 · Cited by 259
Self-citation
Metadata
- Authors
- Wiggin, T. D., Kretzler, M., Pennathur, S., Sullivan, K. A., Brosius, F. C., & Feldman, E. L.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2008-06-26
- Volume
- 149
- Issue
- 10
- Pages
- 4928-4937
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2170456110
- Cited by
- 60
- References
- 1
- FWCI
- 2.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rosiglitazone Treatment Reduces Diabetic Neuropathy in Streptozotocin-Treated DBA/2J Mice. https://app.cochat.ai/papers/10.1210/en.2008-0869
- The paper
- Wiggin, T. D., Kretzler, M., Pennathur, S., Sullivan, K. A., Brosius, F. C., & Feldman, E. L. (2008). Rosiglitazone Treatment Reduces Diabetic Neuropathy in Streptozotocin-Treated DBA/2J Mice. Endocrinology. https://doi.org/10.1210/en.2008-0869
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.